Psoriatic arthritis (PsA) is an inflammatory arthritis of uncertain pathogenesis, affecting approximately one in four patients with psoriasis. Onset of psoriasis typically precedes the development of PsA. Therefore, the dermatologist is ideally positioned to recognize the early signs and symptoms of PsA for diagnosis and subsequent treatment. The role of the dermatologist in early diagnosis and treatment is essential for preventing pain and functional disabilities, as well as the joint deterioration that accompanies progressive forms of PsA. Diagnosis of PsA is a key aspect of the clinical decision process for the dermatologist, as psoriasis plus PsA requires a different therapeutic approach from that required for psoriasis alone. Furthermore, PsA is associated with an increased risk of cardiovascular comorbidities that present significant health concerns. In this review, the pathogenesis and comorbidities of PsA are discussed. In addition, screening and imaging tools that aid in the diagnosis of PsA, as well as tools used for efficacy assessment, are reviewed. Available therapies are presented, with a focus on targeted biologics and emerging treatments. What's already known about this topic? Psoriatic arthritis (PsA) is a significant comorbidity of psoriasis. Physical disability, cardiovascular comorbidities, psychological issues, and a generally poor quality of life negatively impact many to most patients with PsA. Several tools have been developed to aid in PsA diagnosis and assessment. A large body of work has been devoted to researching factors contributing to PsA and developing targeted biologic therapies. What does this study add? Dermatologists are in a position to recognize the early signs of PsA and therefore can be instrumental in achieving the goal of early initiation of adequate therapy. Early intervention may also help slow disease progression and improve patient outcomes. This review may be used by dermatologists as an educational guide on the pathogenesis, screening, diagnosis, comorbidities, existing treatments and emerging therapies for PsA.
ASJC Scopus subject areas